part 8
by: soldier30 11/12/01 09:01 pm
Msg: 1299 of 1302
Gambro BCT and BioTransplant to sponsor a Symposium at ASH detailing the HDM
cell separation product line. At this symposium we expect Gambro BCT to
highlight the strengths of the BCell-SC and TCell-DLI systems both of which are
currently on the market in Europe. Importantly, for the first time at a major
medical conference, we expect Gambro to detail the HDM product portfolio
consists of three lead products:
* Eligix's BCell-HDM, a cell separation technology for the treatment
of B cell malignancies that differentiates itself from the competition.
Eligix's lead product, BCell-HDM, is designed to remove malignant B cells from
autologous BMTs to reduce the risk of the cancer relapsing post transplant and
to reconstitute the patient's immune system function in a rapid fashion.
* Eligix's TCell-HDM, a cell separation system designed to reduce the
incidence of GvHD in allogeneic BMT patients. It has been demonstrated that
the presence of a specific subset of T cells (CD8+ T cells) in the BMT graft
increases the risk of GvHD following a BMT, DLI or a second BMT. The TCell-HDM
system uses HDM coated with anti-CD8 antibodies. By specifically removing the
CD8+ cells in the BMT and DLI, the TCell-HDM system is designed to reduce the
rate of GvHD following allogeneic BMTs and allogeneic DLIs.
* Eligix's PanT-HDM, a cell separation system designed to expand the
pool of potential donors for allogeneic BMT transplants. The Eligix PanT-HDM
product is specifically designed to eliminate all T cells (CD4 and CD8) from
the donor's bone marrow while maintaining high levels of stem cells, progenitor
cells and other ancillary cells in the graft. We believe the PanT-HDM
product's ability to deplete GvHD causing cells from a BMT could broaden the
pool of donors, thus vastly increasing the number of patients who qualify for
an allogeneic transplant.
Near-term events expected to increase visibility for BioTransplant. MedImmune
is aggressively pursuing a MEDI-507 Phase II psoriasis program, which it
expects to complete during 2001. We expect MEDI-507 to enter Phase III
psoriasis trials in 1Q 2002. We also anticipate MedImmune could announce the
complete MEDI-507 Phase II psoriasis trial results during 1H 2002.
We believe BioTransplant is an under-recognized company with extremely
promising technology. We reiterate our BUY rating and $27 price target for
BioTransplant.
KEY EVENTS EXPECTED OVER THE NEXT 12 MONTHS
Initiate Phase I/II AlloMune lymphoma studies
4Q 2001
Initiate pilot AlloMune transplant studies
4Q 2001
Complete enrollment 400-patient MEDI-507 Phase II sub-Q psoriasis trial 4Q
2001
Complete three MEDI-507 Phase II psoriasis trials
4Q 2001
TCell-HDM and Allomune clinical data at ASH
December 2001
Gambro/BioTransplant joint Symposium at ASH
December 9, 2001
Initiate MEDI-507 Phase I/II psoriatic arthritis trials
Early 2002
Initiate MEDI-507 Phase III psoriasis trials
Early 2002
MEDI-507 Phase II psoriasis data
1H 2002
Initiate U.S. Phase III TCell-HDM studies
1H 2002
Initiate Allomune Phase II lymphoma studies
2H 2002
Source: Corporate Reports and Punk, Ziegel & Company estimates
First Call Corporation, a Thomson Financial company.
All rights reserved. 888.558.2500 |
